Company intelligence / Profile preview
Kian Immune Cell Company
Tehran, Tehran Province, Irankiacell-immune.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
NiKogene has reached Phase II clinical development targeting relapsed/refractory pediatric DIPG. The company has completed two Phase I studies with its allogenic NK cell product bank focused on brain tumors. Its products are not yet exported but have the potential to serve a significant portion of domestic cancer patients upon regulatory approval.
- Therapeutic areas
- Oncology
- Modalities
- Allogeneic Natural Killer (NK) cellsGenetically modified immune cellsHematopoietic stem cells3D cell culture models/spheroidsChemobiogram kit for drug sensitivity testing
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Kian Immune Cell Company.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kian Immune Cell Company.